Open AccessRapid Response of a BRCA2/TP53/PTEN -Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report
Author(s) -
Minggui Pan,
Kristen N. Ganjoo,
Amer Karam
Publication year - 2021
Publication title -
the permanente journal/permanente journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.445
H-Index - 30
eISSN - 1552-5775
pISSN - 1552-5767
DOI - 10.7812/tpp/20.251
Subject(s) - olaparib , medicine , gemcitabine , docetaxel , pten , oncology , doxorubicin , temozolomide , leiomyosarcoma , cancer research , chemotherapy , poly adp ribose polymerase , pi3k/akt/mtor pathway , pathology , polymerase , biology , gene , apoptosis , biochemistry
Patients with metastatic uterine leiomyosarcoma (uLMS) have poor prognosis due to limited treatment options, especially when disease progresses on doxorubicin and gemcitabine-docetaxel regimens. Here we report a patient whose metastatic uLMS contains a BRCA2 deep deletion as well as TP53 and PTEN deep deletion. The patient responded rapidly to olaparib, a poly (ADP-ribose) polymerase inhibitor, after progressing on gemcitabine-docetaxel, doxorubicin, and temozolomide regimens. This case report shall be helpful to the treatment of other patients with metastatic uLMS that harbors a BRCA2 mutation or deletion.